{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T16:45:45Z","timestamp":1791305145935,"version":"4.3.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2015,11,16]],"date-time":"2015-11-16T00:00:00Z","timestamp":1447632000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2015,11,16]],"date-time":"2015-11-16T00:00:00Z","timestamp":1447632000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2016,2]]},"DOI":"10.1038\/bmt.2015.273","type":"journal-article","created":{"date-parts":[[2015,11,16]],"date-time":"2015-11-16T09:41:12Z","timestamp":1447666872000},"page":"212-218","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":47,"title":["Thiotepa-based high-dose therapy for autologous stem cell transplantation in lymphoma: a retrospective study from the EBMT"],"prefix":"10.1038","volume":"51","author":[{"given":"L","family":"Sellner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Boumendil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"Finel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Choquet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"de Rosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"Falzetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Scime","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Kobbe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"Ferrara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Delmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"Sayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Amorim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Bouabdallah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Finke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Salles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I","family":"Yakoub-Agha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E","family":"Faber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E","family":"Nicolas-Virelizier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Facchini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Vallisa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E","family":"Zuffa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Sureda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Dreger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the EBMT Lymphoma Working Party","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,11,16]]},"reference":[{"key":"BFbmt2015273_CR1","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1038\/bmt.2009.141","volume":"45","author":"P Ljungman","year":"2010","unstructured":"Ljungman P, Bregni M, Brune M, Cornelissen J, de Witte T, Dini G et al. Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe 2009. Bone Marrow Transplant 2010; 45: 219\u2013234.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2015273_CR2","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1056\/NEJM199512073332305","volume":"333","author":"T Philip","year":"1995","unstructured":"Philip T, Guglielmi C, Hagenbeek A, Somers R, Van der Lelie H, Bron D et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995; 333: 1540\u20131545.","journal-title":"N Engl J Med"},{"key":"BFbmt2015273_CR3","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1016\/S0140-6736(02)08938-9","volume":"359","author":"N Schmitz","year":"2002","unstructured":"Schmitz N, Pfistner B, Sextro M, Sieber M, Carella AM, Haenel M et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial. Lancet 2002; 359: 2065\u20132071.","journal-title":"Lancet"},{"key":"BFbmt2015273_CR4","doi-asserted-by":"publisher","first-page":"4184","DOI":"10.1200\/JCO.2010.28.1618","volume":"28","author":"C Gisselbrecht","year":"2010","unstructured":"Gisselbrecht C, Glass B, Mounier N, Singh Gill D, Linch DC, Trneny M et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol. 2010; 28: 4184\u20134190.","journal-title":"J Clin Oncol."},{"key":"BFbmt2015273_CR5","doi-asserted-by":"publisher","first-page":"3865","DOI":"10.1200\/JCO.2006.06.2117","volume":"24","author":"G Illerhaus","year":"2006","unstructured":"Illerhaus G, Marks R, Ihorst G, Guttenberger R, Ostertag C, Derigs G et al. High-dose chemotherapy with autologous stem-cell transplantation and hyperfractionated radiotherapy as first-line treatment of primary CNS lymphoma. J Clin Oncol 2006; 24: 3865\u20133870.","journal-title":"J Clin Oncol"},{"key":"BFbmt2015273_CR6","doi-asserted-by":"publisher","first-page":"765","DOI":"10.3324\/haematol.2012.076075","volume":"98","author":"E Schorb","year":"2013","unstructured":"Schorb E, Kasenda B, Atta J, Kaun S, Morgner A, Hess G et al. Prognosis of patients with primary central nervous system lymphoma after high-dose chemotherapy followed by autologous stem cell transplantation. Haematologica 2013; 98: 765\u2013770.","journal-title":"Haematologica"},{"key":"BFbmt2015273_CR7","doi-asserted-by":"publisher","first-page":"2512","DOI":"10.1200\/JCO.2007.13.5533","volume":"26","author":"C Soussain","year":"2008","unstructured":"Soussain C, Hoang-Xuan K, Taillandier L, Fourme E, Choquet S, Witz F et al. Intensive chemotherapy followed by hematopoietic stem-cell rescue for refractory and recurrent primary CNS and intraocular lymphoma: Societe Francaise de Greffe de Moelle Osseuse-Therapie Cellulaire. J Clin Oncol 2008; 26: 2512\u20132518.","journal-title":"J Clin Oncol"},{"key":"BFbmt2015273_CR8","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1038\/sj.bmt.1702154","volume":"25","author":"EP Alessandrino","year":"2000","unstructured":"Alessandrino EP, Bernasconi P, Colombo A, Caldera D, Martinelli G, Vitulo P et al. Pulmonary toxicity following carmustine-based preparative regimens and autologous peripheral blood progenitor cell transplantation in hematological malignancies. Bone Marrow Transplant 2000; 25: 309\u2013313.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2015273_CR9","doi-asserted-by":"publisher","first-page":"364","DOI":"10.3324\/haematol.2012.077917","volume":"98","author":"A Korfel","year":"2013","unstructured":"Korfel A, Elter T, Thiel E, Hanel M, Mohle R, Schroers R et al. Phase II study of central nervous system (CNS)-directed chemotherapy including high-dose chemotherapy with autologous stem cell transplantation for CNS relapse of aggressive lymphomas. Haematologica 2013; 98: 364\u2013370.","journal-title":"Haematologica"},{"key":"BFbmt2015273_CR10","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1080\/10428190802340184","volume":"49","author":"R Zaucha","year":"2008","unstructured":"Zaucha R, Gooley T, Holmberg L, Gopal AK, Press O, Maloney D et al. High-dose chemotherapy with BEAM or busulphan\/melphalan and thiotepa followed by hematopoietic cell transplantation in malignant lymphoma. Leuk Lymphoma 2008; 49: 1899\u20131906.","journal-title":"Leuk Lymphoma"},{"key":"BFbmt2015273_CR11","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1038\/bmt.2011.74","volume":"47","author":"S Ganguly","year":"2012","unstructured":"Ganguly S, Jain V, Divine C, Aljitawi O, Abhyankar S, McGuirk J . BU, melphalan and thiotepa as a preparative regimen for auto-transplantation in Hodgkin's disease. Bone Marrow Transplant 2012; 47: 311\u2013312.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2015273_CR12","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1038\/bmt.2009.240","volume":"45","author":"SC Lee","year":"2010","unstructured":"Lee SC, Kim SJ, Lee DH, Kim WS, Suh C, Won JH . Excessive toxicity of once daily i.v. BU, melphalan and thiotepa followed by auto SCT on patients with non-Hodgkin's lymphoma. Bone Marrow Transplant 2010; 45: 801\u2013802.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2015273_CR13","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1038\/sj.bmt.1704672","volume":"34","author":"T Demirer","year":"2004","unstructured":"Demirer T, Ayli M, Fen T, Ozcan M, Arat M, Buyukberber S et al. High-dose thiotepa, melphalan and carboplatin (TMCb) followed by autologous peripheral blood stem cell transplantation in patients with lymphoma\u2014a retrospective evaluation. Bone Marrow Transplant 2004; 34: 781\u2013786.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2015273_CR14","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1179\/102453312X13221316477534","volume":"17","author":"M Di Ianni","year":"2012","unstructured":"Di Ianni M, Ballanti S, Iodice G, Reale A, Falzetti F, Minelli O et al. High-dose thiotepa, etoposide and carboplatin as conditioning regimen for autologous stem cell transplantation in patients with high-risk Hodgkin's lymphoma. Hematology 2012; 17: 23\u201327.","journal-title":"Hematology"},{"key":"BFbmt2015273_CR15","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1080\/10428190500144656","volume":"46","author":"TS Fenske","year":"2005","unstructured":"Fenske TS, Kahl BS, Eickhoff J, Mitchell TL, Smith EP, Atkinson E et al. Excessive toxicity of the high dose thiotepa and etoposide regimen when combined with radiation: long-term autologous transplantation experience in follicular and mantle cell lymphoma. Leuk Lymphoma 2005; 46: 1441\u20131448.","journal-title":"Leuk Lymphoma"},{"key":"BFbmt2015273_CR16","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1038\/sj.bmt.1704110","volume":"32","author":"F Gutierrez-Delgado","year":"2003","unstructured":"Gutierrez-Delgado F, Holmberg L, Hooper H, Petersdorf S, Press O, Maziarz R et al. Autologous stem cell transplantation for Hodgkin's disease: busulfan, melphalan and thiotepa compared to a radiation-based regimen. Bone Marrow Transplant 2003; 32: 279\u2013285.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2015273_CR17","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/sj.bmt.1704312","volume":"33","author":"AG McCoy","year":"2004","unstructured":"McCoy AG, Smith EP, Atkinson ME, Baranski B, Kahl BS, Juckett M et al. A novel preparative regimen for autologous transplant in non-Hodgkin's lymphoma: long-term experience with etoposide and thiotepa. Bone Marrow Transplant 2004; 33: 19\u201324.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2015273_CR18","doi-asserted-by":"publisher","first-page":"427","DOI":"10.3109\/10428199509056853","volume":"17","author":"D Przepiorka","year":"1995","unstructured":"Przepiorka D, Nath R, Ippoliti C, Mehra R, Hagemeister F, Diener K et al. A phase I\u2013II study of high-dose thiotepa, busulfan and cyclophosphamide as a preparative regimen for autologous transplantation for malignant lymphoma. Leuk Lymphoma 1995; 17: 427\u2013433.","journal-title":"Leuk Lymphoma"},{"key":"BFbmt2015273_CR19","first-page":"261","volume":"3","author":"K Schiffman","year":"1997","unstructured":"Schiffman K, Buckner CD, Maziarz R, Maloney DG, Appelbaum FR, Press O et al. High-dose busulfan, melphalan, and thiotepa followed by autologous peripheral blood stem cell transplantation in patients with aggressive lymphoma or relapsed Hodgkin's disease. Biol Blood Marrow Transplant 1997; 3: 261\u2013266.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt2015273_CR20","doi-asserted-by":"publisher","first-page":"2253","DOI":"10.1080\/10428190410001723250","volume":"45","author":"F Waheed","year":"2004","unstructured":"Waheed F, Kancherla R, Seiter K, Liu D, Qureshi Z, Hoang A et al. High dose chemotherapy with thiotepa, mitoxantrone and carboplatin (TMJ) followed by autologous stem cell support in 100 consecutive lymphoma patients in a single centre: analysis of efficacy, toxicity and prognostic factors. Leuk Lymphoma 2004; 45: 2253\u20132259.","journal-title":"Leuk Lymphoma"},{"key":"BFbmt2015273_CR21","doi-asserted-by":"publisher","first-page":"3419","DOI":"10.1182\/blood-2011-04-351924","volume":"118","author":"G Visani","year":"2011","unstructured":"Visani G, Malerba L, Stefani PM, Capria S, Galieni P, Gaudio F et al. BeEAM (bendamustine, etoposide, cytarabine, melphalan) before autologous stem cell transplantation is safe and effective for resistant\/relapsed lymphoma patients. Blood 2011; 118: 3419\u20133425.","journal-title":"Blood"},{"key":"BFbmt2015273_CR22","doi-asserted-by":"publisher","first-page":"3029","DOI":"10.1182\/blood-2014-08-596668","volume":"124","author":"G Visani","year":"2014","unstructured":"Visani G, Stefani PM, Capria S, Malerba L, Galieni P, Gaudio F et al. Bendamustine, etoposide, cytarabine, melphalan, and autologous stem cell rescue produce a 72% 3-year PFS in resistant lymphoma. Blood 2014; 124: 3029\u20133031.","journal-title":"Blood"},{"key":"BFbmt2015273_CR23","first-page":"736","volume":"49","author":"RL Heideman","year":"1989","unstructured":"Heideman RL, Cole DE, Balis F, Sato J, Reaman GH, Packer RJ et al. Phase I and pharmacokinetic evaluation of thiotepa in the cerebrospinal fluid and plasma of pediatric patients: evidence for dose-dependent plasma clearance of thiotepa. Cancer Res 1989; 49: 736\u2013741.","journal-title":"Cancer Res"},{"key":"BFbmt2015273_CR24","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s11060-014-1411-8","volume":"118","author":"MC Chamberlain","year":"2014","unstructured":"Chamberlain MC . Salvage therapy with bendamustine for methotrexate refractory recurrent primary CNS lymphoma: a retrospective case series. J Neurooncol 2014; 118: 155\u2013162.","journal-title":"J Neurooncol"},{"key":"BFbmt2015273_CR25","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1007\/s11060-011-0788-x","volume":"107","author":"JJ Renfrow","year":"2012","unstructured":"Renfrow JJ, Detroye A, Chan M, Tatter S, Ellis T, McMullen K et al. Initial experience with bendamustine in patients with recurrent primary central nervous system lymphoma: a case report. J Neurooncol 2012; 107: 659\u2013663.","journal-title":"J Neurooncol"},{"key":"BFbmt2015273_CR26","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1093\/annonc\/mdl327","volume":"18","author":"V Boehme","year":"2007","unstructured":"Boehme V, Zeynalova S, Kloess M, Loeffler M, Kaiser U, Pfreundschuh M et al. Incidence and risk factors of central nervous system recurrence in aggressive lymphoma\u2014a survey of 1693 patients treated in protocols of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). Ann Oncol 2007; 18: 149\u2013157.","journal-title":"Ann Oncol"},{"key":"BFbmt2015273_CR27","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1016\/j.bbmt.2006.03.016","volume":"12","author":"C Aggarwal","year":"2006","unstructured":"Aggarwal C, Gupta S, Vaughan WP, Saylors GB, Salzman DE, Katz RO et al. Improved outcomes in intermediate- and high-risk aggressive non-Hodgkin lymphoma after autologous hematopoietic stem cell transplantation substituting intravenous for oral busulfan in a busulfan, cyclophosphamide, and etoposide preparative regimen. Biol Blood Marrow Transplant 2006; 12: 770\u2013777.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt2015273_CR28","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/bmt.2008.429","volume":"44","author":"MP Escalon","year":"2009","unstructured":"Escalon MP, Stefanovic A, Venkatraman A, Pereira D, Santos ES, Goodman M et al. Autologous transplantation for relapsed non-Hodgkin's lymphoma using intravenous busulfan and cyclophosphamide as conditioning regimen: a single center experience. Bone Marrow Transplant 2009; 44: 89\u201396.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2015273_CR29","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1038\/sj.bmt.1705841","volume":"40","author":"JG Kim","year":"2007","unstructured":"Kim JG, Sohn SK, Chae YS, Yang DH, Lee JJ, Kim HJ et al. Multicenter study of intravenous busulfan, cyclophosphamide, and etoposide (i.v. Bu\/Cy\/E) as conditioning regimen for autologous stem cell transplantation in patients with non-Hodgkin's lymphoma. Bone Marrow Transplant 2007; 40: 919\u2013924.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2015273_CR30","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/bmt.2008.298","volume":"43","author":"RZ Yusuf","year":"2009","unstructured":"Yusuf RZ, Dey B, Yeap BY, McAfee S, Attar E, Sepe PS et al. Autologous SCT with a dose-reduced BU and CY regimen in older patients with non-Hodgkin's lymphoma. Bone Marrow Transplant 2009; 43: 37\u201342.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2015273_CR31","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1016\/j.bbmt.2015.02.005","volume":"21","author":"YB Chen","year":"2015","unstructured":"Chen YB, Lane AA, Logan BR, Zhu X, Akpek G, Aljurf MD et al. Impact of conditioning regimen on outcomes for patients with lymphoma undergoing high-dose therapy with autologous hematopoietic cell transplantation. Biol Blood Marrow Transplant 2015; 21: 1046\u20131053.","journal-title":"Biol Blood Marrow Transplant"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/bmt2015273.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bmt2015273","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bmt2015273.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,23]],"date-time":"2022-03-23T15:04:53Z","timestamp":1648047893000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/bmt2015273"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11,16]]},"references-count":31,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,2]]}},"alternative-id":["BFbmt2015273"],"URL":"https:\/\/doi.org\/10.1038\/bmt.2015.273","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,11,16]]},"assertion":[{"value":"4 May 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2015","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2015","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 November 2015","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was supported by a restricted grant from Riemser Pharma, Greifswald, Germany. LS and PD received honoraria from Riemser Pharma, Greifswald, Germany.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}